The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: Early data from a single-institute survey

• DOI: 10.1016/j.ejca.2021.05.006
• Publication Date: 2021-05-26T02:57:27Z
• Authors: Vincenzo Di Noia; Davide Renna; Vittoria Barberi; Mattia Di Civita; Federica Riva; Giulia Costantini; Emanuela Dell’ Aq...; Michelangelo Russ...; Domenico Bracco; Antonia Marina La...; Diana Giannarelli; Francesco Cognetti
• Keywords: Adult; Aged, 80 and over; Male; 0301 basic medicine; COVID-19 Vaccines; SARS-CoV-2; Vaccination; COVID-19; Middle Aged; 3. Good health; Young Adult; 03 medical and health sciences; Italy; Vaccination Refusal; ChAdOx1 nCoV-19; Neoplasms; Surveys and Questionnaires; Humans; Female; BNT162b2; COVID-19; Cancer patients; Public health; Refusal; SARS-CoV-2; Vaccine; BNT162 Vaccine; Original Research; Aged

Patients with cancer have an increased risk of complications from coronavirus disease 2019 (COVID-19) infection, including death, and thus, they were considered as high-priority subjects for COVID-19 vaccination. We report on the compliance with the COVID-19 vaccine of patients affected by solid tumours.Patients with cancer afferent to Medical Oncology 1 Unit of Regina Elena National Cancer Institute in Rome were considered eligible for vaccination if they were receiving systemic immunosuppressive antitumor treatment or received it in the last 6 months or having an uncontrolled advanced disease. The Pfizer BNT162b2 vaccine was proposed to all candidates via phone or during a scheduled visit. The reasons for refusal were collected by administrating a 6-item multiple-choice questionnaire.From 1st March to 20th March 2021, of 914 eligible patients, 102 refused vaccination (11.2%, 95% confidence interval [CI] 9.1-13.2). The most frequent (>10%) reasons reported were concerns about vaccine-related adverse events (48.1%), negative interaction with concomitant antitumor therapy (26.7%), and the fear of allergic reaction (10.7%). The refusal rate (RR) after 15th March (date of AstraZeneca-AZD1222 suspension) was more than doubled compared with the RR observed before (19.7% versus 8.6%, odds ratio [OR] 2.60, 95% CI 1.69-3.99; P < 0.0001). ECOG-PS 2 was associated with higher RR compared with ECOG-PS 0-1 (OR 2.94, 95% CI 1.04-8.34; P = 0.04). No statistically significant differences in RR according to other clinical characteristics were found.Our experience represents the first worldwide report on the adherence of patients with cancer to COVID-19 vaccination and underlines how regulatory decisions and media news spreading could influence the success of the campaign.